Intelligent Medicine Original, leveraging its proprietary AI drug design platform TranProteins, has successfully developed a GLP-1 receptor agonist (GLP-1 RA) with an extended half-life and enhanced efficacy. The next-generation GLP-1 RA boasts a half-life (T1/2) three times longer than semaglutide,…
Recently, Professor Zhangsheng Yu, the founder of Intelligent Medicine Original Medical Technology (Shanghai), led his team to collaborate with an international pharmaceutical company. Their research, titled “Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver…
Recently, Professor Haifeng Chen, co-founder of company, developed an innovative and efficient new protein sequence design method called GPD. Compared to the current state-of-the-art method, proteinMPNN, GPD exhibits significantly higher sequence diversity and generates sequences 2.2 times faster, greatly enhancing…
Recently, the team of Professor Zhangsheng Yu, the founder of the company, and their collaborators published a research paper titled “Harnessing TME depicted by histological images to improve cancer prognosis through a deep learning system” in the Cell sub-journal “Cell…
